ClinicalTrials.gg
CompletedNCT00775411Updated Sep 3, 2012Results posted

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

A Phase 2 interventional study of dexamethasone and ranibizumab in Choroidal Neovascularization and Age-Related Maculopathy, sponsored by Allergan. Completed at 3 sites in 3 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
29th of 45
44 · median 62
Started
2008
with 4 others
Phase 2
10 of 45
none open now
Registered
19th of 45
by date
Lead sponsor
1 of 45
Allergan

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 29th largest by enrollment, is one of 5 that started in 2008, is one of 10 in phase 2, and was the 19th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.

03

Conditions studied

  • Choroidal Neovascularization
  • Age-Related Maculopathy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50 years of age or older with active subfoveal choroidal neovascularization (CNV) secondary to AMD
  • Central retinal thickness ≥ 300 µm
  • Visual acuity between 20/400 and 20/32
  • Eligible for Anti-VEGF therapy

Exclusion criteria

Exclusion Criteria:

  • Previous treatment for CNV due to AMD
  • High eye pressure
  • Glaucoma
  • Uncontrolled systemic disease
  • Known allergy to the study medications
  • Recent eye surgery or injections in the eye
  • Female subjects that are of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    700 µg dexamethasone and ranibizumab

    700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.

    Drug: dexamethasone · Biological: ranibizumab

Interventions

  • 700 µg dexamethasone intravitreal injection at Day 1 in the study eye.

    Also known as: Posurdex

  • Biologicalranibizumab

    Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.

    Also known as: Lucentis®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4

    Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed on the study eye after pupil dilation at baseline and Week 4.

    Time frame: Baseline, Week 4

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 26

    BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

    Time frame: Baseline, Week 26

  2. Percentage of Participants With Fluorescein Leakage Improved, Unchanged and Worsened From Baseline as Assessed by Fluorescein Angiography at Week 26

    Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA at Week 26 was compared to FA at Baseline. The percentage of participants in each of the following categories is reported: Improved (Leakage area decreased \>=10%), Unchanged (Leakage area changed \< 10%) and Worsened (Leakage area increased \>=10%).

    Time frame: Baseline, Week 26

07

Results

Posted Sep 3, 2012

Participant flow

Participant flow — Overall Study
Milestone700 µg Dexamethasone + Ranibizumab
Started44
Completed43
Not completed1

Outcome measures

PrimaryChange From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4

Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina, was performed on the study eye after pupil dilation at baseline and Week 4.

Time frame:
Baseline, Week 4
Reported as:
Mean · Microns
Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4
Microns700 µg Dexamethasone + Ranibizumab
Baseline360.9 ± 69.23
Change from baseline at Week 4-62.0 ± 78.68
SecondaryChange From Baseline in Best Corrected Visual Acuity (BCVA) at Week 26

BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

Time frame:
Baseline, Week 26
Reported as:
Mean · Number of letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 26
Number of letters700 µg Dexamethasone + Ranibizumab
Baseline46.5 ± 17.73
Change from baseline at Week 264.5 ± 9.62
SecondaryPercentage of Participants With Fluorescein Leakage Improved, Unchanged and Worsened From Baseline as Assessed by Fluorescein Angiography at Week 26

Fluorescein angiography (FA) is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. FA at Week 26 was compared to FA at Baseline. The percentage of participants in each of the following categories is reported: Improved (Leakage area decreased \>=10%), Unchanged (Leakage area changed \< 10%) and Worsened (Leakage area increased \>=10%).

Time frame:
Baseline, Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With Fluorescein Leakage Improved, Unchanged and Worsened From Baseline as Assessed by Fluorescein Angiography at Week 26
Percentage of participants700 µg Dexamethasone + Ranibizumab
Improved74.4
Unchanged18.6
Worsened7.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
700 µg Dexamethasone + Ranibizumab—6/44 (13.6%)9/44 (20.5%)
Most frequent serious events
Most frequent serious events
Event700 µg Dexamethasone + Ranibizumab
AnaemiaBlood and lymphatic system disorders1/44
Cardio-respiratory arrestCardiac disorders1/44
Coronary artery diseaseCardiac disorders1/44
EndophthalmitisInfections and infestations1/44
FallInjury, poisoning and procedural complications1/44
GastroenteritisInfections and infestations1/44
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/44
Urinary tract infectionInfections and infestations1/44
Most frequent other events
Most frequent other events
Event700 µg Dexamethasone + Ranibizumab
Conjunctival haemorrhageEye disorders6/44
Intraocular pressure increasedInvestigations3/44

Baseline characteristics

Age Continuous
Age Continuous(Years)700 µg Dexamethasone + Ranibizumab
Mean72.3 ± 10.43
Sex: Female, Male
Sex: Female, Male(Participants)700 µg Dexamethasone + Ranibizumab
Female25
Male19
08

Study locations

3 sites
  • San Antonio, Texas, United States
  • Sydney, New South Wales, Australia
  • Manila, Philippines
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Nov 2009 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 2 years 10 months after primary completion. A results delay was requested in Sep 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2008
First posted
Oct 20, 2008
Start
Nov 2008
Primary completionActual
Nov 2009
CompletionActual
Apr 2010
Results delay requested
Sep 24, 2010
Results first posted
Sep 3, 2012
Last update
Sep 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00775411
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 20, 2008
Start date
Nov 2008
Primary completion
Nov 2009
Completion
Apr 2010
Results posted
Sep 3, 2012
Last update
Sep 3, 2012

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Ranibizumab

Start the discussion